NGF and Alzheimer disease: Some phase I clinical trials and an open-label study have used gene therapy procedures to inject AD patients with human-derived NGF, genetically engineered using human vectors (autologous [40] or heterologous [41, 42]) or derived from adenoviruses [43, 44].